Kremezin

ApprovedSmall molecule

Astellas

Kremezin is one of 99 small molecule programs targeting Endothelial Dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endothelial DysfunctionActive, not recruiting

Oxidative StressActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Endothelial DysfunctionApproved

Active, not recruiting

Oxidative StressApproved

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Kremezin

Astellas

Approved

1 2

Aranesp

Amgen

Preclinical

40 3

Glucotrol

Pfizer

Preclinical

1 4

Vemlidy

Gilead

Preclinical

1 5

Lorelco

Sanofi

Preclinical

1 6

Activase

Roche

Preclinical

—7

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Genotropin

EMD Serono

Preclinical

1 9

Viagra

VViatris Specialty LLC

Preclinical

1 10

Sodium Valproate

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxidative Stress1 trial

Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation

Completed·TTungs' Taichung Metroharbour Hospital·Phase 4·NCT01458652·30 enrolled

Chronic Kidney Disease1 trial

Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease

Completed·IInstitute for Health Outcomes and Process Evaluation Reseach·Phase 4·NCT00456859·450 enrolled

Endothelial Dysfunction1 trial

The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease

Unknown status·EEwha Womans University·Phase 4·NCT01157260·30 enrolled

Unspecified1 trial

Pharmacokinetic Study of ASP1517 With Kremezin®

Completed· Astellas logo

Astellas·Phase 1·NCT02693613·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Kremezin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kremezin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kremezin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Astellas

Kremezin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oxidative Stress1 trial

Chronic Kidney Disease1 trial

Endothelial Dysfunction1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News